Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 7Phase 4 5Phase 1/2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 2Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5NET 3Gastrointestinal 1

Conditions

Neuroendocrine Tumors 3Pituitary Neoplasms 1Neuroendocrine Tumour With Carcinoid Symptoms 1Gigantism 1Gastro-enteropancreatic neuroendocrine tumor 1Acromegaly 1

Interventions

lanreotide 5Octreotide 5Everolimus 4Dexmedetomidine 3Cabergoline 3pasireotide 2Phenoxybenzamine 2Carboplatin 2trametinib 1testosterone enanthate 1surufatinib 1selpercatinib 1pralsetinib 1pegvisomant 1lutetium Lu 177 dotatate 1lenvatinib 1larotrectinib 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entrectinib 1dabrafenib 1candesartan 1arginyllysine 1anlotinib 1Vitamin D 1Trimethoprim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 4 × lanreotide × Endocrine × Clear all
NCT05701241 2024-06-14

SAUNA

University Hospital, Antwerp

Phase 4 Recruiting
270 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT01861717 2021-09-30

A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

Saint John's Cancer Institute

Phase 4 Terminated
4 enrolled 5 charts
Endocrine

Acromegaly, Gigantism, Pituitary Neoplasms

NCT00681187 2019-11-22

SAPHE

Ipsen

Phase 4 Completed
26 enrolled 18 charts
Endocrine

Neuroendocrine Tumour With Carcinoid Symptoms

NCT02075606 2019-06-07

CALM-NET

Ipsen

Phase 4 Completed
50 enrolled 12 charts
EndocrineNET

Neuroendocrine Tumors

NCT03083210 2019-05-20

Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

Samsung Medical Center

Phase 4 Unknown
28 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡